This research data suggested that insulin treatment could attenuate the progression of sarcopenia in patients with type 2 diabetes.[102] Sugimoto et al[103] showed that correction of poor glycemic control and use of insulin were significantly associated with the increase in skeletal muscle mass or gait speed in Japanese patients with type 2 diabetes. The gene discussed is INS; the disease is type 2 diabetes mellitus.